A Phase 3 interventional study of sitagliptin phosphate and Comparator: metformin hydrochloride in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2017-05-11.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 10th largest by enrollment of the 197 interventional ones that give a count, is one of 17 that started in 2007, is one of 74 in phase 3, and was the 24th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 78 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 17 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,050 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 13th largest by enrollment of the 170 interventional ones that give a count, is one of 19 that started in 2007, is one of 86 in phase 3, and was the 21st registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to evaluate the efficacy and safety of sitagliptin in comparison to a commonly used medication in patients with type 2 diabetes
General Inclusion Criteria:
General Exclusion Criteria:
Drug
Drug: sitagliptin phosphate
Active comparator
Drug: Comparator: metformin hydrochloride
(1) sitagliptin 100mg tablet once daily (q.d.) for a 24-wk treatment period
Also known as: MK0431
(4) Metformin 500mg tablets once daily (q.d.) for a 24-wk treatment period.
Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24
HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.
Time frame: Baseline and 24 weeks
Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Diarrhea
Time frame: Baseline to Week 24
Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Nausea
Time frame: Baseline to Week 24
Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Abdominal Pain
Time frame: Baseline to Week 24
Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Vomiting
Time frame: Baseline to Week 24
First patient In: 04-Apr-2007 Last Patient Last Visit: 25-Jul-2008 113 study centers worldwide
| Milestone | Sitagliptin 100 mg | Metformin |
|---|---|---|
| Started | 528 | 522 |
| Completed | 467 | 447 |
| Not completed | 61 | 75 |
| Withdrew: Adverse event | 9 | 19 |
| Withdrew: Trial terminated ( site closed) | 1 | 0 |
| Withdrew: Lack of efficacy | 10 | 1 |
| Withdrew: Lost to follow-up | 9 | 14 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Protocol violation | 14 | 15 |
| Withdrew: Withdrawal by subject | 16 | 23 |
| Withdrew: Glycemic discontinuation criteria | 1 | 1 |
HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.
| Percent | Sitagliptin 100 mg | Metformin |
|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 | -0.43 (-0.48 to -0.38) | -0.57 (-0.62 to -0.51) |
| Participants | Sitagliptin 100 mg | Metformin |
|---|---|---|
| Patients Who Reported Diarrhea | 19 | 57 |
| Patients Who Did Not Report Diarrhea | 509 | 465 |
| Participants | Sitagliptin 100 mg | Metformin |
|---|---|---|
| Patients Who Reported Nausea | 6 | 16 |
| Patients Who Did Not Report Nausea | 522 | 506 |
| Participants | Sitagliptin 100 mg | Metformin |
|---|---|---|
| Patients Who Reported Abdominal Pain | 11 | 20 |
| Patients Who Did Not Report Abdominal Pain | 517 | 502 |
| Participants | Sitagliptin 100 mg | Metformin |
|---|---|---|
| Patients Who Reported Vomiting | 2 | 7 |
| Patients Who Did Not Report Vomiting | 526 | 515 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin 100 mg | — | — | — |
| Metformin | — | — | — |
| Event | Sitagliptin 100 mg | Metformin |
|---|---|---|
| Any Cardiac disordersCardiac disorders | 1/528 | 3/522 |
| Any Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications | 3/528 | 0/522 |
| Any Infections and infestationsInfections and infestations | 2/528 | 2/522 |
| Acute myocardial infarctionCardiac disorders | 0/528 | 1/522 |
| Coronary artery diseaseCardiac disorders | 0/528 | 1/522 |
| TachyarrhythmiaCardiac disorders | 0/528 | 1/522 |
| Any Congenital, familial and genetic disordersCongenital, familial and genetic disorders | 0/528 | 1/522 |
| Multiple endocrine adenomatosis Type IICongenital, familial and genetic disorders | 0/528 | 1/522 |
| Any General disorders and administration site conditionsGeneral disorders | 0/528 | 1/522 |
| Non-cardiac chest painGeneral disorders | 0/528 | 1/522 |
| Event | Sitagliptin 100 mg | Metformin |
|---|---|---|
| Any Gastrointestinal disordersGastrointestinal disorders | 19/528 | 57/522 |
| DiarrhoeaGastrointestinal disorders | 19/528 | 57/522 |
| Age, Continuous(years) | Sitagliptin 100 mg | Metformin | Total |
|---|---|---|---|
| Mean | 55.9 ± 10.7 | 56.1 ± 10.4 | 56.0 ± 10.6 |
| Sex: Female, Male(Participants) | Sitagliptin 100 mg | Metformin | Total |
|---|---|---|---|
| Female | 278 | 288 | 566 |
| Male | 250 | 234 | 484 |
| Race/Ethnicity, Customized(participants) | Sitagliptin 100 mg | Metformin | Total |
|---|---|---|---|
| White | 397 | 395 | 792 |
| Black | 24 | 19 | 43 |
| Asian | 64 | 62 | 126 |
| Other | 43 | 46 | 89 |
| Body Weight(Kilograms) | Sitagliptin 100 mg | Metformin | Total |
|---|---|---|---|
| Mean | 84.9 ± 17.7 | 84.6 ± 17.2 | 84.7 ± 17.5 |
| Hemoglobin A1c (HbA1c)(Percent) | Sitagliptin 100 mg | Metformin | Total |
|---|---|---|---|
| Mean | 7.2 ± 0.7 | 7.3 ± 0.7 | 7.3 ± 0.7 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Mar 2007 to primary completion in Jul 2008, 16 months.
Results were first posted in Aug 2009, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 16 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin